Preclinical Prevent Cancer Treatment Program (PREVENT): Toxicology and Pharmacology Testing

IDIQ

Description

The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. Research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.

Overview

Ceiling

$19,000,000

Primary Sponsoring Agency

National Cancer Institute (NCI) [HHS - NIH]

Who Can Use

One Agency

Primary NAICS

541711 - Research And Development In Biotechnology

Primary PSC

AN11 - Health R&D Services; Health Care Services; Basic Research

Primary Set Aside

None

Extent Competed

Full And Open Competition

Related Opportunity

Preclinical PREVENT Cancer Program- Toxicology and Pharmacology Testing (N01CN45009-45)

Preclinical Prevent Cancer Treatment Program (PREVENT): Toxicology and Pharmacology Testing awarded by National Cancer Institute (NCI) in September 2015 accepts orders through September 2018. The IDIQ has a reported ceiling of $19,000,000, and as of today, $9,820,557 has been obligated through the vehicle with a total reported backlog of $77,873. The IDIQ was awarded full & open and has a primary NAICS code of 541711.

Award Hierarchy

Vehicle

Preclinical Prevent Cancer Treatment Program (PREVENT): Toxicology and Pharmacology Testing

Indefinite Delivery Vehicles

Prime Contracts

Subcontracts

Status

Period of Performance

9/22/15

Start Date

9/24/18

Ordering Period End Date

100% Complete

Task Order Obligations and Backlog

$9.8M

Total Obligated

$9.8M

Current Award

$9.9M

Potential Award

99% Funded

$0.0

Funded Backlog

$77.9K

Total Backlog

Vehicle Award Share

Contractors with greatest percentage of obligations for Preclinical Prevent Cancer Treatment Program (PREVENT): Toxicology and Pharmacology Testing

Vehicle Award Share

Federal Award Analysis